Page 1

SARTORIUS Press Release Aubagne , April 21 , 2021 First - quarter results of Sartorius Stedim Biotech Sales revenue up 61.1 percent to 655 million euros ; underlying EBITDA margin 35.4 percent A good 23 percentage points of growth contributed by the coronavirus pandemic Accelerated expansion of production capacities in all regions on track as planned Sartorius Stedim Biotech , a leading partner of the biopharma industry , had an exceptionally strong start to fiscal 2021 and grew substantially in order intake¹ , sales revenue and earnings . This was fueled by strong fundamental growth , additional business from vaccine manufacturers , and acquisitions . " Many of our products play an essential role in helping to overcome the pandemic . In addition to a very positive general business performance in the first quarter , we accordingly experienced strong demand for our products and technologies used in the production of vaccines and achieved a sharp increase in sales . The substantial rise in the company's profit margin was also supported by underproportionate development of costs , such as the low number of business trips as well as fewer new hires in non - production areas . These effects are expected to decrease as the year progresses . In many areas , we are working at the limits of our capacity and are therefore continuing to move ahead with accelerating the expansion of our production facilities and are hiring additional employees , " said Joachim Kreuzburg , Chairman of the Board of Directors and CEO . In the first three months of the current year , Sartorius Stedim Biotech has already created some 600 new jobs ; the Group now employs around 8,200 people in total . Group sales revenue surged by 61.1 percent to around 655 million euros in constant currencies ( reported : +55.2 percent ) , benefiting from the ramp - up in coronavirus vaccine production by many manufacturers . The comparative base for these high growth figures , though , is the relatively low prior - year quarter , which did not yet include any pandemic - related business or an acquisition that was consolidated as of May 2020 . In the first quarter , acquisitions² contributed about 8 percentage points to growth while the contribution attributable to businesses related to the coronavirus pandemic was a good 23 percentage points . Order intake¹ grew even more dynamically than sales revenue , almost doubling to 1,004 million euros ( in constant currencies : +95.9 percent of which a good 37 percentage points were related to the coronavirus ; reported : +87.8 percent ) . Part of this high order intake is due to the changed ordering patterns of some customers who in the current situation have been placing their orders further in advance than usual . Underlying EBITDA¹ climbed to 232 million euros , up from 127 million euros a year earlier ( +82.8 percent ) . The corresponding margin rose to 35.4 percent ( Q1 2020 : 30.0 percent ) . Economies of scale as well as the pandemic - related underproportionate cost development contributed to this rise in profitability . Relevant net profit¹ for the Group soared by 87.4 percent to 151 million euros ; underlying earnings per share¹ were 1.64 euros ( Q1 2020 : 0.88 euros ) . 1 | 9